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Abstract
The syndrome of inappropriate antidiuretic hormone se-
cretion (SIADH) remains a challenging disorder to diag-
nose and treat. Three cases are presented to illustrate these
challenges. The first two cases had drug-induced SIADH
secondarytoaselectiveserotoninreuptakeinhibitor(forde-
pression) or carbamazepine (for trigeminal neuralgia). The
thirdcasehadSIADHpossiblysecondarytobronchiectasis.
The lowest serum sodium concentrations ranged between
118and124mmol/Linthethreecases.Hyponatraemiawas
not acute and severe symptoms were absent. However, sev-
eral mild neurological symptoms were present. In the first
case, hyponatraemia likely contributed to a fall, which re-
sulted in a fracture of the odontoid process of the axis. The
other two cases also had gait disturbances, in addition to
nausea, headache, impaired memory, difficulty concentrat-
ing and confusion. In at least two of the cases, the underly-
ing cause of SIADH was impossible to reverse. Traditional
treatment for SIADH with fluid restriction and demeclo-
cycline failed, caused side effects or increased duration of
hospitalstay.Theseexamplessuggestaneedforbettertreat-
ment options. The introduction of the vasopressin-receptor
antagonists for SIADH may be a welcome new therapy to
overcome some of these challenges.
Keywords: bronchiectasis; carbamazepine; demeclocycline; selective
serotonin reuptake inhibitor; vasopressin-receptor antagonists
Introduction
Thesyndromeofinappropriatesecretionofantidiuretichor-
mone (SIADH) is one of the more common causes of hy-
ponatraemia and is characterized by an inability to dilute
urine despite hypoosmolality [1]. Both diagnosis and treat-
ment of SIADH can be difficult. Below, we present three
cases to illustrate the current challenges of SIADH.
Case 1
A 78-year-old woman was brought to the hospital after a
fall on the stairs. She had a past medical history of hyper-
tension and atrial fibrillation, for which she took a calcium
channel blocker, a coumarin derivative and a beta blocker.
A selective serotonin reuptake inhibitor (SSRI), sertraline
(40 mg q.d.), had been prescribed by her general practi-
tioner 2 months before, because of complaints of depres-
sion following the death of her son. She reported climbing
a flight of stairs with a glass of water in her hand. The
next moment she was lying on the ground not remember-
ing what had happened. Before the fall she experienced
thirst for a number of days, but did not report other com-
plaints. She apparently had a normal diet with normal salt
intake. At presentation, she indicated severe pain in her
head and neck. On physical examination, she had several
bruises on her head and she was disoriented to time and
place. The blood pressure was 120/90 mm Hg, and she had
an irregular pulse of 80 beats per minute. She did not have
apparent signs of extracellular fluid volume contraction. A
computed tomography scan of her cervical spine revealed a
fractureoftheodontoidprocessoftheaxis(typeIIIaccord-
ing to the Anderson and d’Alonzo classification), which
was treated with a halo-frame and physiotherapy. By serum
chemistry, hyponatraemia was found (Table 1). Because
of the known association between sertraline and hypona-
traemia [2], and because her biochemical profile suggested
SIADH (Table 1), sertraline was discontinued and she was
placedonafluidrestriction(1.0L/day).Serumsodiumrose
to 134 mmol/L in 5 days. Physical rehabilitation was com-
menced, and serum sodium was checked periodically and
remained normal (137–139 mmol/L). She was able to cope
without the antidepressant.
Case 2
A 53-year-old woman was referred to our outpatient clinic
because of recurrent complaints of nausea. In addition,
her general practitioner had repeatedly found a low serum
sodiumconcentration.Shehadaprevioushistoryoftrigem-
inal neuralgia, which had proved difficult to treat. Previ-
ously, pregabalin, gabapentin and oxcarbazepine had been
tried,buteithergaveserioussideeffectsorinsufficientpain
relief.Theoptionofmicrovasculardecompressionhadbeen
discussed with the neurosurgeon, but had been deferred
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Table 1. Clinical and laboratory characteristics of three SIADH cases
Case 1 Case 2 Case 3 References
Clinical data
Gender and age 78, female 53, female 66, male
Presentation Fall Nausea, hyponatraemia Confusion, headache,
unsteadiness
Cause of SIADH Sertraline Carbamazepine Bronchiectasis?
Serum values
Sodium, mmol/L 125 128 118 136–145
Potassium, mmol/L 4.2 4.3 3.9 3.5–5.1
Creatinine, μmol/L 46 56 60 55–90 (♀)
65–115 (♂)
Urea, mmol/L 4.7 4.5 2.8 2.5–7.5
Uric acid, mmol/L 0.18 0.15 - 0.2–0.42
Osmolality, mOsm/kg 255 265 249 275–300
Endocrine tests
TSH, mU/L 2.10 4.07 0.9 0.4–4.3
Cortisol, nmol/L 1095 287 327 → 693a 200–800a
Urine values
Sodium, mmol/L 44 65 58 –
Osmolality, mOsm/kg 523 426 547 –
aBefore and 30 minutes after 250 μg synthetic ACTH. The normal response is a rise in serum cortisol to ≥ 500 nmol/L after 60 minutes. Reference for
cortisol is for ∼9.00 am.
TSH, thyroid-stimulating hormone; SIADH, syndrome of inappropriate antidiuretic hormone secretion.
for the time being. Her neurologist had accepted hypona-
traemia as an unavoidable side effect of carbamazepine,
one of the few drugs that could relieve her trigeminal neu-
ralgia. It was currently under control by a combination of
carbamazepine (400 mg b.i.d.) and amitriptyline (10 mg
q.d.). She complained of nausea, forgetfulness and diffi-
culty concentrating. Most of these complaints had been
present for a number of years. She also admitted gait insta-
bility during her weekly game of tennis. She had a normal
diet, and was believed to have normal water and salt in-
take. Her blood pressure was 120/80 mm Hg, her pulse was
60 beats per minute. Physical examination was unremark-
able and she neither had oedema nor orthostatic changes
(clinicaleuvolaemia).Herpreviouslaboratorytestsshowed
chronic hyponatraemia with serum sodium levels fluctuat-
ing between 124 and 135 mmol/L since 2004. Her current
laboratory results are shown in Table 1. Because of the bio-
chemical data (Table 1) together with carbamazepine and
amitriptyline use, SIADH appeared the most obvious diag-
nosis, although adrenal insufficiency could not formally be
excluded on the basis of a random cortisol value. Because
the neurologist determined that the carbamazepine was es-
sential to the patient, we advised the patient to limit fluid
intake to 1 L/day, and to contact the hospital in situations of
fever,diarrhoea,vomitingortheprescriptionofanewdrug.
We explained the likely connection between her symptoms
and her chronic hyponatraemia to her neurologist, and ad-
vised to check serum sodium levels at regular intervals.
Because this patient was recently seen in our outpatient
clinic, the response in serum sodium and symptomatology
to fluid restriction remains to be determined.
Case 3
A 66-year-old man presented to the emergency room with
symptoms of confusion, unsteadiness and headaches. He
had a previous history of psoriasis and frequent respira-
tory tract infections (two to three per year), which often
required antibiotic treatment, but for which no formal di-
agnosis had been made. He had a 30 pack year smoking
history. He did not use medication. Based on his symp-
toms, his general practitioner suspected a brain tumour or
early-onset dementia. His blood pressure was 126/80 lying
and 130/84 standing, with a regular pulse of 88 bpm. He
hadnooedemaandhisjugularvenouspressurewasnormal.
Further physical examination was unremarkable.
He turned out to have hyponatraemia of 118 mmol/L
(Table 1). Computed tomography was performed and re-
vealedpulmonarybronchiectasis(anewfinding),whilethe
head and abdomen scans were normal. Subsequent bron-
choscopy was normal, and sputum cytology and brushings
were negative for cancer and tuberculosis. In an additional
work-up for hyponatraemia, hypothyroidism and adrenal
insufficiency were excluded (Table 1). Therefore, based
on clinical euvolaemia and the biochemical data (Table
1), the working diagnosis was SIADH possibly secondary
to bronchiectasis. He was placed on fluid restriction (800
mL/day), which increased serum sodium to 126 mmol/L
in 6 days. In parallel, his gait improved, confusion and
headaches disappeared, whereas his memory still remained
impaired. He was discharged with the advice to maintain
the fluid restriction, and visited the outpatient clinic two
weeks later. He reported a recurrence of headaches. His
serum sodium concentration had fallen to 122 mmol/L. Al-
ternative treatment for SIADH was started in the form of
demeclocycline(300mgthreetimesdaily).Twoweekslater
serum sodium had risen to 130 mmol/L, and the patient felt
well again with improved memory. However, another two
weeks later, he developed polyuria and polydipsia with a
serum sodium concentration of 152 mmol/L. Demeclocy-
cline was temporarily discontinued, and then reintroduced
athalfdose,producingaserumsodiumof140mmol/L.De-
spite achieving this stable situation, demeclocycline had toiii22 N. van der Lubbe et al.
bewithdrawnagain,becausePUVA-therapy(psoraleneand
ultraviolet radiation) was started for psoriasis, and deme-
clocycline is very photosensitizing. Consequently, hypona-
traemiareemergedwithaserumsodiumof126mmol/Lde-
spite a fluid restriction of 1000 mL/day. His serum sodium
currently remains in the range between 121–129 mmol/L,
andhecontinuestoexperienceheadaches,cognitivedecline
(<126 mmol/L) and gait unsteadiness (<122 mmol/L).
Discussion
The three cases represent common clinical examples of
SIADH, with which most clinicians may be familiar. Be-
low, the mechanisms of SIADH in the three cases will be
discussed briefly, followed by a discussion of the clinical
dilemmas that SIADH posed in these patients.
Mechanisms of SIADH
SSRI-induced hyponatraemia (Case 1) was first reported
with the use of sertraline in 1993 [3]. In 1996, Liu et al.
reviewed 736 cases of SSRI-induced hyponatraemia (30
published cases, 706 cases reported to monitoring bodies
and the pharmaceutical industry). They found that hypona-
traemia may occur with all major SSRIs, including fluoxe-
tine,paroxetine,sertralineandfluvoxamine[4].Fabianetal.
conducted a prospective study in 75 subjects who started
with paroxetine after a major depressive episode had been
diagnosed [5]. Hyponatraemia developed in nine patients
(12%). Their serum sodium concentrations fell from 137 ±
2t o1 2 8± 2 mmol/L, and this took 9.3 ± 4.7 days. Inter-
estingly,vasopressinlevelsinnormonatraemicandhypona-
traemic patients were normal, and did not differ between
groups. However, ‘normal’ vasopressin levels during hy-
potonicity could still be considered inappropriate, because
hypotonicity should normally suppress vasopressin. In rats,
chronic administration of sertraline did increase levels of
vasopressin and oxytocin, suggesting hyponatraemia to be
a central phenomenon [6]. In contrast, in a rat-model of
fluoxetine-induced hyponatraemia, vasopressin levels re-
mained unchanged [7]. Instead, a 40% increase in the ex-
pressionofthewaterchannelaquaporin-2waterintherenal
collecting duct was shown, suggesting a direct renal effect
of the drug.
The reported incidence of carbamazepine-induced hy-
ponatraemia (Case 2) ranges between 4 and 22% [8,9].
For oxcarbazepine, the keto-analogue of carbamazepine,
the incidence appears even higher with 51% [10]. Def-
inite risk factors remain unclear, but age, serum carba-
mazepinelevelsandconcomitantdrugsaffectingelectrolyte
balance have all been implicated [11]. Carbamazepine was
first marketed as a drug to treat trigeminal neuralgia (for-
merly known as tic douloureux) in 1962. The first two
cases of carbamazepine-induced hyponatraemia were re-
ported in 1977 [12,13]. Since, several mechanisms have
been proposed for carbamazepine-induced hyponatraemia
[14], and they are probably not mutually exclusive. The
first two case reports found elevated levels of vasopressin
(1.7 and 4.0 pg/mL with serum osmolalities of 261 and
257 mOsm/kg, respectively) [12,13], suggesting the most
simple explanation, namely that carbamazepine stimulates
vasopressinsecretion.Inanotherreport,however,Meinders
et al. had described the opposite, a decrease in vasopressin
with carbamazepine; they therefore suggested a renal ef-
fect [15]. This would be in agreement with the finding that
carbamazepine is able to improve the polyuria of central
diabetes insipidus, in which endogenous vasopressin se-
cretion is virtually absent [16]. Stephens et al. proposed a
combined central andrenaleffect[17].Intheirexperiments
inhealthyvolunteers,theyshowedthatwithcarbamazepine
vasopressinlevelsroselessduringwaterdeprivationandfell
less during water loading. Thus, they concluded that ‘under
the influence of carbamazepine the osmoreceptors become
lazy’ [17]. However, they also observed impaired diuresis
during carbamazepine, despite similar vasopressin concen-
trations at peak diuresis with carbamazepine and control.
They therefore proposed that carbamazepine also increased
renal sensitivity to ‘normal’ vasopressin levels. Because
carbamazepine-induced water retention did not suppress
vasopressin, this was additional evidence that resetting of
the osmoreceptors must also have occurred. Toad bladder
experiments, however, were unable to confirm a renal ef-
fect, because carbamazepine did not affect osmotic water
flow nor did it potentiate the response to vasopressin [18].
Theuseofamitriptylinemayalsohavecontributedtohy-
ponatraemia in Case 2. The mechanism of amitriptyline in
hyponatraemia remains elusive. The evidence here consists
solely of case reports [19,20].
Althoughcitedinreviews[21],themechanismofSIADH
in bronchiectasis is also unclear. It probably shares fea-
tureswithotherpulmonarydiseasesthatcancauseSIADH,
including cystic fibrosis [22], pneumonia [23], asthma
[24] and chronic obstructive pulmonary disease [25]. Sev-
eral pathophysiological scenarios have been discussed for
SIADH in these diseases, including a reset osmostat, an
effect on baroreceptors or a direct effect of hypercapnia on
vasopressinrelease[26,27].Sincemanyofthesepulmonary
diseases are also characterized by infection, the relation be-
tween the acute phase response and hyponatraemia, which
is becoming increasingly clear [28], is also of interest. In
fact, recent animal data show an intriguing interaction be-
tween interleukin-6 and vasopressin release [29]. Because
data on bronchiectasis and SIADH are limited, it is im-
portant to emphasize that it is difficult to be sure about
their relationship in Case 3. Alternatively, other causes of
SIADH may become apparent over time, or SIADH may
turn out to be idiopathic.
Challenges of SIADH
The three cases illustrate several of the aspects of SIADH
and its treatment that were discussed in the previous ar-
ticles of this supplement. All three patients had chronic
hyponatraemia, and severe symptoms such as seizures and
coma were absent. However, they did have other more sub-
tle neurological symptoms to which hyponatraemia likely
contributed. Hyponatraemia may have caused the fall in
Case 1, and the headache, nausea, attention deficits, gait
instability and memory loss in Cases 2 and 3. In fact, these
symptoms strikingly resemble those described in the study
by Renneboog et al. [30]. These authors suggested thatChallenges of SIADH iii23
chronic hyponatraemia should no longer be considered an
asymptomatic condition as is often suggested. Indeed, the
neurologist of Case 2 had accepted chronic hyponatraemia
as a side effect of carbamazepine, without advising fluid
restriction. Because these subtle neurological symptoms
in chronic hyponatraemia (unsteadiness, difficulty concen-
trating, reduced attention span, mild confusion, mild per-
sonality change) have just recently been clarified [30], it
is conceivable that physicians ascribe these symptoms to
the underlying disease or the patient’s personality rather
than to the—reversible—hyponatraemia per se. In the case
of drug-induced SIADH (Cases 1 and 2)—and before the
advent of vaptans—physicians had to weight the impor-
tance of treating the underlying disorder against the burden
on the patient from the hyponatraemic side effects of the
treatment. An interesting new example of this dilemma was
recently described for imatinib, which was given for acute
lymphoblastic leukaemia, but also induced SIADH [31].
If patients and physicians agree that the neurological
symptoms—albeit subtle—of chronic hyponatraemia are
too important to ignore, this means that monitoring and
treatment of hyponatraemia should be given consideration.
As reviewed in this supplement, several treatment options
are available, each with their specific advantages and dis-
advantages. A role for the new selective vasopressin V2-
receptor antagonists in these clinical examples is not dif-
ficult to imagine. In Cases 1 and 2, a vaptan would have
enabled the patients to benefit from the drugs without hy-
ponatraemia as a side effect. This is even more evident in
Case3.Inhim,currenttreatmentsfailedtocorrectachronic
SIADHwithhyponatraemia.Treatingthesideeffectsofone
drugwithyetanotherdrugmaynotbethemostelegant way
of practicing medicine. However, in specific cases it may
still prove the best approach for both patient and physician.
If vasopressin-receptor antagonists are used, the next
question is for how long. This is especially important for
transient causes of SIADH. When the stimulus for inap-
propriate vasopressin release fades, hypernatraemia lies
in wait, although an intact thirst mechanism and access
to water should prevent this. A practical approach could
be to discontinue the vasopressin-receptor antagonist for
3–4 days at given intervals (maybe every 4–6 weeks), to
evaluate whether hyponatraemia recurs or not. In hospi-
talized patients, transient SIADH may be common and
vasopressin-receptor antagonists may help here to shorten
the hospital stay. Although rare in the clinical trials, the
risk of overly rapid correction of chronic hyponatraemia
remains a concern, because it may lead to the osmotic de-
myelinationsyndrome.Ifoverlyrapidcorrectionofchronic
hyponatraemiadoesoccur,infusionofdextrose5%inwater
and perhaps even administration of dDAVP may be neces-
sary to bring the serum sodium down to the desired level as
a prophylaxis against permanent brain damage [32]. Taken
together, the introduction of the vaptans is an interesting
addition—if applied in the right circumstances—to the cur-
rent armamentarium for hyponatraemia, and may give the
patient more comfort and the physician a better therapy
for hyponatraemia secondary to SIADH. We are now at the
doorwaytoanentirelynewtreatmentareaandcannotbecer-
tain of what lays beyond. How useful will it really turn out
to be? How many more patients with hyponatraemia shall
we discover once the therapeutic progress opens our minds
to hyponatraemia—‘How many fish will be in the pond?’
We just don’t know. But then that’s part of the fun—things
may get better.
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